# Cannabis Suppositories for Menstrual Pain – Realm of Caring Foundation > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-suppositories-for-menstrual-pain-realm-of-caring-foundation/ > **Published:** 2026-05-28T10:39:53-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:53:57-04:00 > **Clinical Summary:** Cannabis suppositories for menstrual pain show theoretical promise but lack rigorous clinical trials. Evidence, safety, and clinical guidance for clinicians. --- ✦ New CED Clinical Relevance #76 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PainCBDResearchSafetyDosing Why This Matters Clinicians treating patients with menstrual pain should be aware that cannabis suppositories represent an emerging delivery method with potential local [anti-inflammatory effects](https://cedclinic.com/cbd-antioxidative-anti-inflammatory-properties-benefits/), though current evidence from single studies is insufficient to establish efficacy or safety compared to established treatments. The lack of detectable THC in formulations addresses [psychosis risk](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) concerns, but clinicians need robust clinical trial data before recommending this approach over evidence-based therapies like NSAIDs or hormonal contraceptives. Patients seeking cannabis for menstrual symptoms require counseling about the absence of rigorous efficacy data and potential risks from unregulated products with variable CBD content and potency. Clinical Summary # Clinical Summary This article examines the use of cannabis suppositories, specifically a broad-spectrum high-CBD formulation without detectable THC, for management of menstrual pain. The approach represents an emerging nonpharmacologic option for dysmenorrhea, a condition affecting many reproductive-age individuals for whom conventional NSAIDs and hormonal contraceptives may be ineffective or contraindicated. The high-CBD, THC-free formulation may minimize psychoactive effects while potentially leveraging cannabidiol’s anti-inflammatory and analgesic properties, though the evidence base remains limited to preliminary studies rather than large randomized controlled trials. The vaginal/rectal route of administration may offer localized therapeutic effects while reducing systemic exposure compared to oral or inhaled routes. Clinicians should recognize that while some patients report symptom relief with such products, robust clinical evidence supporting efficacy and safety for menstrual pain specifically is still developing, and patients should be counseled about the current knowledge gaps. For patients interested in cannabis-based approaches to dysmenorrhea, discussions should include the limited evidence, potential drug interactions, and the importance of consulting with providers knowledgeable in both gynecology and [cannabinoid pharmacology](https://cedclinic.com/cannabinoid-drug-interactions-clinical-evidence/). Dr. Caplan’s Take “What we’re seeing with vaginal and rectal suppositories is a delivery method that bypasses hepatic metabolism entirely, allowing us to achieve sustained local [anti-inflammatory effects](https://cedclinic.com/cbd-antioxidative-anti-inflammatory-properties-benefits/) where patients actually need them, and in my practice I’ve found women often require significantly lower systemic doses to manage dysmenorrhea when we use this route rather than oral cannabis.” Clinical Perspective While anecdotal reports and preliminary evidence suggest that cannabis suppositories may offer local anti-inflammatory and analgesic effects for menstrual pain, the current evidence base remains limited to small studies and observational data, making it difficult to establish efficacy or optimal dosing in clinical populations. The pharmacokinetics of rectally administered cannabinoids differ substantially from inhaled or oral routes, and most research has focused on systemic rather than localized therapeutic effects, creating uncertainty about whether local delivery actually provides clinical advantages for dysmenorrhea. Healthcare providers should be cautious about formulations claiming specific cannabinoid ratios (such as high-CBD, no-THC products) without robust clinical validation, as manufacturing standards and [quality control](https://cedclinic.com/alabama-medical-cannabis-commission-audit-violations/) remain inconsistent across producers. When patients inquire about cannabis suppositories for menstrual pain, practitioners can acknowledge the theoretical rationale while being transparent about the lack of comparative data against established treatments like NSAI 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/pain-management/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20Suppositories%20for%20Menstrual%20Pain%20-%20Realm%20of%20Caring%20Foundation%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56618)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56618)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20Suppositories%20for%20Menstrual%20Pain%20-%20Realm%20of%20Caring%20Foundation%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D56618)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://realmofcaring.org/cannabis-suppositories-for-menstrual-pain/](https://realmofcaring.org/cannabis-suppositories-for-menstrual-pain/) Further Reading CED Clinic Blog[The First Cannabis Drug to Earn FDA Breakthrough Therapy Status for Pain`](https://cedclinic.com/fda-breakthrough-therapy-ver-01-cannabis-chronic-back-pain/) Cannabis Policy Wire[The DEA’s New Cannabis Registration System May Matter More Than Legalization Headlines](https://cedclinic.com/dea-cannabis-registration-portal-medical-normalization/) Research Digest[Research Digest: 20 Recent Studies – May 02, 2026](https://cedclinic.com/cannabinoid-based-interventions-autism-safety-effectiveness-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).